It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report issued on Tuesday. Other analysts also recently issued research ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...